Palbociclib
Palbociclib works by blocking the activity of proteins called CDK4 and CDK6 that control how fast cells grow. Blocking these proteins may slow or stop the growth of cancer cells. Palbociclib is a type of targeted therapy drug called a kinase inhibitor. It is a small-molecule drug (a drug that can enter cells easily).
FDA label information for this drug is available at DailyMed.
Use in Cancer
Palbociclib is approved to be used with other drugs to treat:
- Breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-) and has spread. It is used:
- with fulvestrant in adults whose cancer has gotten worse after treatment with hormone therapy
- with an aromatase inhibitor in postmenopausal women and in men who have not been treated with hormone therapy
Palbociclib is also being studied in the treatment of other types of cancer.
More About Palbociclib
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Palbociclib - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Experimental Medulloblastoma Treatment Gets a Boost with Nanoparticles
Clinical Trials Accepting Patients
Find Clinical Trials for Palbociclib - Check for trials from NCI's list of cancer clinical trials now accepting patients.